chrisvoncsefalvay/vaers-outcomes huggingface dataset:
noted mild swelling and a small knot was felt in his left arm at the injection site; left arm pain; fatigue; headache; muscle pain; nausea; chills; noted mild swelling and a small knot was felt in his left arm at the injection site; joint pain; This spontaneous case was reported by a nurse and describes the occurrence of VACCINATION SITE SWELLING (noted mild swelling and a small knot was felt in his left arm at the injection site), PAIN IN EXTREMITY (left arm pain), FATIGUE (fatigue), HEADACHE (headache) and MYALGIA (muscle pain) in a 20-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011J20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Drug allergy (Albuterol allergy), Latex allergy, Drug allergy (Tylenol allergy), Drug allergy (Amoxicillin allergy) and Drug allergy (Augmentin allergy).    On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Mar-2021, the patient experienced VACCINATION SITE SWELLING (noted mild swelling and a small knot was felt in his left arm at the injection site), PAIN IN EXTREMITY (left arm pain), FATIGUE (fatigue), HEADACHE (headache), MYALGIA (muscle pain), NAUSEA (nausea), CHILLS (chills), INJECTION SITE INDURATION (noted mild swelling and a small knot was felt in his left arm at the injection site) and ARTHRALGIA (joint pain). At the time of the report, VACCINATION SITE SWELLING (noted mild swelling and a small knot was felt in his left arm at the injection site), PAIN IN EXTREMITY (left arm pain), FATIGUE (fatigue), HEADACHE (headache), MYALGIA (muscle pain), NAUSEA (nausea), CHILLS (chills), INJECTION SITE INDURATION (noted mild swelling and a small knot was felt in his left arm at the injection site) and ARTHRALGIA (joint pain) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications or treatment details reported. It was explained to the patient that these are side effects of the vaccine and, if his condition worsened, he was to follow up with his medical provider and he was also to follow up with our onsite nurse.    Most recent FOLLOW-UP information incorporated above includes: On 03-May-2021: NNI On 04-May-2021: Additional info-2 : VAERS
received a dose of an expired vial; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (received a dose of an expired vial) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Jun-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (received a dose of an expired vial). On 04-Jun-2021, EXPIRED PRODUCT ADMINISTERED (received a dose of an expired vial) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.   ? No treatment information was provided.   This case was linked to MOD-2021-211360, MOD-2021-211360 (Patient Link).
Systemic: Dizziness / Lightheadness-Severe, Systemic: Nausea-Severe, Additional Details: Pt laid flat on the back at event then recovered in about 10-15 minutes
17 year old minor was accidently given Moderna shot #1 in April 2021. Given shot Modera #2 today one month prior to 18th birthday in accordance with CDC guidance ( off label ) use.
Chest pain starting at June 29,2022 at 13:50, and continuing.  Low fever (99.9F/37.7C) since 23:30 of June 28, 2022
sore throat; running nose; Headache; cold sore of mouth; sore arm; injection site redness; This spontaneous case was reported by a consumer and describes the occurrence of OROPHARYNGEAL PAIN (sore throat), RHINORRHOEA (running nose), ORAL PAIN (cold sore of mouth), PAIN IN EXTREMITY (sore arm) and INJECTION SITE ERYTHEMA (injection site redness) in a 59-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Jan-2021, the patient experienced PAIN IN EXTREMITY (sore arm) and INJECTION SITE ERYTHEMA (injection site redness). On 12-Jan-2021, the patient experienced ORAL PAIN (cold sore of mouth). On 14-Jan-2021, the patient experienced OROPHARYNGEAL PAIN (sore throat), RHINORRHOEA (running nose) and HEADACHE (Headache). At the time of the report, OROPHARYNGEAL PAIN (sore throat), RHINORRHOEA (running nose), ORAL PAIN (cold sore of mouth), PAIN IN EXTREMITY (sore arm), INJECTION SITE ERYTHEMA (injection site redness) and HEADACHE (Headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. No treatment information was provided.
Felt sick for a week after vaccination; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Felt sick for a week after vaccination) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016M20A) for COVID-19 vaccination.     Concurrent medical conditions included Diabetic. Concomitant products included INSULIN for Diabetic.    On 10-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Felt sick for a week after vaccination). At the time of the report, VACCINATION COMPLICATION (Felt sick for a week after vaccination) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment information was reported   This case was linked to MOD-2021-067693 (Patient Link).
NORMAL COMMON SYMPTOMS FIRST THREE DAYS, EVERY 4 OR 5 DAYS FLU LIKE SYMPTOMS NO FEVER. WEEK THREE HIVE LIKE BUMPS ON BOTH ARMS SMALL BUMPS ON FOREHEAD, LOSS OF APPETITE, KIDNEY, LIVER PAIN, BACK ACNE. COGNITIVE CLARITY LOSS.
Mild headache the next day for 1 day; This is a spontaneous report  from a Pfizer-sponsored program. A non-contactable consumer (patient) reported a patient of unspecified age and gender received dose 1 of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE) via an unspecified route of administration on an unspecified date as a single dose for COVID-19 immunization. Medical history and concomitant medications were not reported. On an unspecified date, the patient experienced mild headache the next day for 1 day. The outcome of mild headache was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
I have been post menopause for two years and after receiving shot on July 23 I got a very light period on August 14
Narrative:  COVID infection following COVID vaccine series 04/12 Janssen, dose #1 08/08 pt cc: cough, fatigue, fever, myalgias, lack of appetite, headache, exposure: unknown 08/13 Pt admit ED (outside facility) cc: SOB dx: unknown LOC: 1 day 08/13 CXR impression: New spiculated 1 cm opacity projecting over the right upper lobe. This could be further characterized with chest CT. 08/13 SARS-COV-2 LINEAGE AY.3 0/13 SARS-COV-2 CLADE 21A DELTA 08/13 COVID swab, result: detected 08/14- 08/23 pt symptoms continue 08/24 COVID swab, result: detected 08/24 clinically resolved 09/20 CT chest impression: 1. Pleural based pulmonary opacities bilaterally may represent thickening/scarring, recommend follow-up with FULL INSPIRATION chest CT scan in 6 months. Alternatively if prior CT scans become available, comparison may preclude the necessity for further evaluation. Other findings as above.
Persistent menstruation. Despite being on birth control, I bled for over 3 months straight.  Finally I bled through a diva cup in 3 hours and went back to the doctor. After doing blood work and an ultrasound to rule out other causes,  they told me to take 2400mg of ibuprofen a day.  This seems to be controlling the bleeding,  but if I try to wean off of it,  I begin menstruating again.
Body Pain, Tiredness, High Fever, Headache. From Next day o5/08/2012 Big Red, Hot bumps on the spot where the vaccine got. Its so paining ..Its almost big as medium tomato... and rashes here and there and small pimple kind of bumps all over the body ..Its itching and burning ..
pt recv vax 30JUN95 & APR96 pt exp full-blown chicken pox;reporter had a concern about the particular lot of vax;reporter reported 3 patients;
He received Hib and DTP/DTap vaccinations on 04/Jun/2009 and developed pain and sore at the injection site.  He cried when I was holding him up, especially touching his arms.  He was difficult to hold his bottle and picked up things.
Pt received Pfizer x2.  Pt tested COVID + on 8/29/21 and admitted to hospital for COVID on 8/31/2021. Pt received remdesivir, dexamethasone, doxycycline, and tocilizumab during hospitalization. Pt was discharged to rehab on 3L O2 nasal cannula on 9/9/21.
first Shingrix dose in October of 2019 / not received their second dose yet; This case was reported by a consumer via call center representative and described the occurrence of incomplete course of vaccination in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose (intramuscular) 0.5 ml in unknown arm in October 2019).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.  Additional details provided were as follows: This case was reported by patient herself. The age at vaccination was not applicable for this report. Till the time of reporting, the patient did not receive the 2nd dose. which led to incomplete course of vaccination. The reporter did not consent to follow-up. This case had been linked with US2021103256, reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021103256:same reporter. husband case.
Discontinued pfizer monovalent 6mo-4yr , No adverse reaction reported by parent.
Sore arm; Feeling weak; Black/blue spots; Dizzy; Could not eat; Itching; She could not lift her arm; Red egg circle shape; Nausea; Chills; Tired; Headache; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore arm), ASTHENIA (Feeling weak), VACCINATION SITE SCAR (Black/blue spots), DIZZINESS (Dizzy) and DECREASED APPETITE (Could not eat) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 018821A and 022M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 31-Mar-2021 at 10:00 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 31-Mar-2021, the patient experienced PAIN IN EXTREMITY (Sore arm), ASTHENIA (Feeling weak), VACCINATION SITE SCAR (Black/blue spots), DIZZINESS (Dizzy), DECREASED APPETITE (Could not eat), PRURITUS (Itching), VACCINATION SITE ERYTHEMA (Red egg circle shape), NAUSEA (Nausea), CHILLS (Chills), FATIGUE (Tired) and HEADACHE (Headache). 31-Mar-2021, the patient experienced INJECTED LIMB MOBILITY DECREASED (She could not lift her arm). The patient was treated with ASPIRIN [ACETYLSALICYLIC ACID] for Adverse event, at a dose of 1 dosage form. On 02-Apr-2021, ASTHENIA (Feeling weak), VACCINATION SITE SCAR (Black/blue spots), DIZZINESS (Dizzy), DECREASED APPETITE (Could not eat), VACCINATION SITE ERYTHEMA (Red egg circle shape), NAUSEA (Nausea), CHILLS (Chills) and FATIGUE (Tired) had resolved. At the time of the report, PAIN IN EXTREMITY (Sore arm), PRURITUS (Itching) and INJECTED LIMB MOBILITY DECREASED (She could not lift her arm) outcome was unknown and HEADACHE (Headache) had resolved.            No relevant concomitant medications were reported.  Treatment medication includes Gatorade for the symptoms   Most recent FOLLOW-UP information incorporated above includes: On 02-Apr-2021: Follow-up information received: date of birth of the patient was updated On 20-Jul-2021: Follow up was received : Contain Non significant information
A patient (40 year old Male) was given Moderna for their first dose and incorrectly given Pfizer as a second dose; This spontaneous case was reported by a pharmacist and describes the occurrence of INTERCHANGE OF VACCINE PRODUCTS (A patient (40 year old Male) was given Moderna for their first dose and incorrectly given Pfizer as a second dose) in a 40-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 053E21A) for COVID-19 vaccination.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for COVID-19 vaccination.    No Medical History information was reported.   On 23-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 20-Sep-2021, the patient received second dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (Intramuscular) .3 ml. On 20-Sep-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INTERCHANGE OF VACCINE PRODUCTS (A patient (40 year old Male) was given Moderna for their first dose and incorrectly given Pfizer as a second dose). On 20-Sep-2021, INTERCHANGE OF VACCINE PRODUCTS (A patient (40 year old Male) was given Moderna for their first dose and incorrectly given Pfizer as a second dose) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was provided. No treatment medication was provided.   Most recent FOLLOW-UP information incorporated above includes: On 20-Sep-2021: Additional information received contains patient demographics and contact details were updated.
This spontaneous report was received from a female patient of unknown age who was reporting on herself. Information on the patient's medical history, concurrent conditions and concomitant medications were not reported. On an unknown date, the patient was vaccinated with ZOSTAVAX (strength, dose, frequency, route of administration, lot# and expiry date was not reported) for prophylaxis. On an unknown date, the patient had several cold sores on her lips that have broken out. Outcome of the event was unknown. The reporter's causality assessment was not provided.
Received COVID-19 booster 10/1/21. On 10/2/21, patient began experiencing injection site swelling and generalized pruritis. On 10/5/21, she began experiencing itchiness in her throat with trouble swallowing and itchiness in both knees, eyes, scalp, and neck. She took Diphenhydramine 50 mg and found some relief.   Discharge plan: Prednisone 20 mg tablet (60 mg PO QD for 5 days), Famotidine 40 mg PO QD, Diphenhydramine 50 mg PO Q4-6H
Little Sore pain in the shot area for up to eight weeks  - mostly off and on- Noticeable the most pain on week 6. Side-note, did-not use any gyms or any other physical labor of the arms for work activities.
Symptoms: Skin rash & urticarial pruritus Treatment: METHYLPREDNISOLONE 4 MG UD
Immediate shortness of breath, then dizziness and syncope resulting in fall and laceration to forehead and under chin.
I was fine one minute and then I was not fine.  My nose started to run like a garden hose.  I had a low-grade headache.  The next night I had a dry cough.  That went on for a day with the nose.  The throat disappeared.  My nose is still running.  The night if the 7th I did a COVID test and then again on the 8th and they were negative.  On the 9th I took another one and it was positive.  I went to an urgent care, and they did a rapid test which was negative and then a PCR which was positive.  I had Paxlovid at home and started to take it.  I started Paxlovid on the 10th of October.
pt was given shot  on 5/3/19 in the morning, with no reaction.  on 5/4/19 about 1:30 am, patient woke up  shivering, then at 2:30 am, had fever and severe headache. patient's arm was very sore and very tender, and patient had muscle ache all throughout the body; patient had no diarrhea, no belly pain, not throwing up, not itching.  patient took tylenol about mid-morning and about 1- 2 hours after, was feeling a little better.  patient noticed her bp early morning was much higher than usual.  rph advised to monitor bp and her blood sugar, too. rph will contact md on monday.
Altered mental status, began 3-20-18. Disorientation, combativeness, followed by mania.
Received expired second dose; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Received expired second dose) in a 55-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 014F21A and 037f21a) for COVID-19 vaccination.     No Medical History information was reported.   On 03-Sep-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Oct-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Received expired second dose). On 01-Oct-2021, EXPIRED PRODUCT ADMINISTERED (Received expired second dose) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant product use was reported. No treatment information was provided.  The patient received expired second dose.   This case was linked to MOD-2021-347607, MOD-2021-346406, MOD-2021-346347, MOD-2021-346608, MOD-2021-346268, MOD-2021-347607, MOD-2021-346421, MOD-2021-347067, MOD-2021-347112, MOD-2021-346981 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 14-Oct-2021: Follow-up information includes reporter email id.
Site: Bruising at Injection Site-Medium, Site: Itching at Injection Site-Mild, Site: Pain at Injection Site-Medium, Site: Redness at Injection Site-Mild
My lips became numb, then my tongue and the tip of my nose began to tingle.  I took Benadryl about 20 minutes after onset (when I got home), and the tingling stopped within 30 minutes.  The numbness wore off after an hour or so.  I felt normal by evening.  No recurrence.  Headaches that night and over the next day.
persistent muscle soreness in left arm (site of injection) with onset of increased pain with movement, stiffness and decreased range of motion noted 9 days after receiving vaccine. Pt used occasional doses of ibuprofen or tylenol without much relief and has  not been evaluated by a medical provider as of yet. Self referred to physical therapy which he will see on 12/1/2021.
the pt received an injection in his right arm.  he began to notice increasing pain and swelling of his right arm and chest muscles on the right side.  he presented to our emergency room and was found to have significant muscle swelling and tenderness of his right arm and right anterior chest wall.  he was also noted to be in rhabdomyolysis with ck's greater than 15,000.
Hardness at injection site; Swelling at injection site; Redness at the injection site; Tiredness; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE INDURATION (Hardness at injection site), VACCINATION SITE SWELLING (Swelling at injection site), VACCINATION SITE ERYTHEMA (Redness at the injection site) and FATIGUE (Tiredness) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 020B21A) for COVID-19 vaccination.     Concurrent medical conditions included Penicillin allergy.    On 01-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Apr-2021, the patient experienced VACCINATION SITE INDURATION (Hardness at injection site), VACCINATION SITE SWELLING (Swelling at injection site), VACCINATION SITE ERYTHEMA (Redness at the injection site) and FATIGUE (Tiredness). At the time of the report, VACCINATION SITE INDURATION (Hardness at injection site), VACCINATION SITE SWELLING (Swelling at injection site), VACCINATION SITE ERYTHEMA (Redness at the injection site) and FATIGUE (Tiredness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment information has given as, ice pack. List of concomitant medication were not given.
Cold like symptoms and fever 101, we discuss using TYLENOL for fever and contacting her PCP.
Pt reports started hurting at injection site continue thru day then radiating down arm, lifting arm felt like pulling inside arm.  Treated with ice, no response called facility 8/27/10 in am told to use warm compress, Aleve.
Patients have been administered from vaccines that experienced a temperature excursion; Patients have been administered from vaccines that experienced a temperature excursion; This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Patients have been administered from vaccines that experienced a temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Patients have been administered from vaccines that experienced a temperature excursion) in a 25-year-old female patient who received mRNA-1273 (Spikevax) (batch no. 027L21A) for COVID-19 vaccination.     No Medical History information was reported.    On 15-Mar-2022, the patient received first dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form. On 15-Mar-2022, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Patients have been administered from vaccines that experienced a temperature excursion). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Patients have been administered from vaccines that experienced a temperature excursion). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Patients have been administered from vaccines that experienced a temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Patients have been administered from vaccines that experienced a temperature excursion) outcome was unknown.        For mRNA-1273 (Spikevax) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported. Date of temperature excursion was 10-Mar-2022. Maximum or minimum temperatures reached was 64 degrees Fahrenheit. Excursion duration was approximately 7 hours. The vaccine was stored in refrigerator at the time of the excursion. There were no changes in visual inspection. Pertinent details: At the time they were unpunctured. Vaccine was administered on 15-Mar-2022 and vials were returned to the refrigerator. Tran date was 15-Mar-2022.The patient did not experience any adverse events post injection. No treatment medications were reported.